This phenomenon might be related to the protective effect of estrogen on insulin resistance, lipid accumulation, hepatic VLDL secretion, lipotoxicity, and inhibition the activation of JNK and NF-кB in the progression of NAFLD (43–47). Here, MAPK8 is linked to metabolic dysfunction-associated steatotic liver disease.